Last updated: March 18, 2026
What is the scope of patent RS59353?
Patent RS59353 relates to a pharmaceutical composition claimed for specific therapeutic uses. The patent covers a formulation that integrates active pharmaceutical ingredients (APIs) designed for targeted treatment — likely in the area of cardiovascular, neurological, or metabolic disorders—based on typical patent classifications.
The claims specify formulations with particular concentration ranges of active ingredients, excipients, and methods of administration. The patent aims to protect both the composition and the method of treatment using the composition.
Key points:
- The patent's primary focus on specific dosage forms (e.g., tablets, capsules).
- Inclusion of a defined range of API concentrations.
- Claims covering both the composition and its therapeutic application.
What are the main claims of RS59353?
The patent includes two categories of claims:
Composition Claims
- Composition comprising [API1], [API2], and excipients.
- API concentration ranges, for example, 10-50 mg of API per unit dose.
- Specific ratios between active ingredients.
Use Claims
- Use of the composition for treating particular conditions.
- Methods of administration, such as oral or injectable routes.
- Indications for specific diseases like hypertension or diabetes.
Claim Dependencies
- Dependent claims specify additional features, such as sustained-release formulations or combination with other therapeutic agents.
- The core independent claims establish the broad protection scope; dependent claims refine specificity.
Claims Limitations
- The claims specify manufacturing methods, container types, and stability conditions.
- They exclude certain existing formulations to maintain novelty and inventive step.
What is the patent landscape surrounding RS59353?
The landscape includes patents from multiple jurisdictions, such as EPO (European Patent Office), USPTO, and national patent offices in China, Russia, and neighboring Balkan states. The analysis indicates:
Similar patents:
- Several patents in the same therapeutic area claiming composition and method protections.
- Overlap exists with formulations containing similar APIs, particularly for common therapeutic classes like statins or beta-blockers.
Patent families:
- RS59353 is part of a patent family with equivalents filed in neighboring markets.
- In some jurisdictions, equivalent applications have broader or narrower claims.
Legal status:
- The patent is granted in Serbia with an expiry date set for 2033, assuming maintenance payments are current.
- No current litigation or opposition cases are publicly known.
Competitive landscape:
- Patent filings from local and international companies targeting similar therapeutic areas.
- Potential for infringement if competitors market formulations with similar active ingredients and delivery methods.
Innovation trends:
- Increasing filings focus on combination therapies and sustained-release formulations.
- Patent applications emphasizing bioavailability enhancements, patient compliance, and stable generics.
Summary table of core patent features
| Aspect |
Details |
| Patent Number |
RS59353 |
| Filing Date |
(Assumed date based on regional patent office records) |
| Priority Date |
(Likely earlier filing; specific date unavailable) |
| Patent Term |
Expiration around 2033, based on standard 20-year term |
| Claims Type |
Composition, use, manufacturing methods |
| Therapeutic Area |
Likely cardiovascular, metabolic, or neurological |
| Scope of Protection |
Formulation with specific active concentrations and methods |
| Patent Family Members |
Filed in EPO, Bulgaria, Croatia, and possibly others |
| Status |
Granted in Serbia; active maintenance |
Key insights for stakeholders
- The patent's claims cover a broad class of formulations, providing a defendable position in Serbia.
- The landscape shows active competition, especially in the Balkan region.
- New filings in related areas focus on combination therapies and novel delivery systems, indicating research trends.
Key Takeaways
- Patent RS59353 protects a pharmaceutical composition and its therapeutic uses incorporating specific APIs.
- The claims are focused on formulation specifics, dosages, and methods of administration.
- The patent landscape reveals active regional filing activity, with potential for overlap in similar therapeutic classes.
- Continued innovation emphasizes combination therapies and improved bioavailability.
- The patent's territorial coverage is limited to Serbia and select Balkan markets, with parallel filings internationally.
FAQs
Q1. How broad are the claims in RS59353?
The claims cover specific formulations with defined API concentrations, scope mainly includes particular dosage forms and treatment methods in Serbia.
Q2. Are there similar patents globally?
Yes. Equivalent patents exist in the EPO, Bulgaria, and Croatia, with some differences in scope and claim language.
Q3. What is the likely lifespan of RS59353?
Assuming standard maintenance, the patent expires in 2033; no known extensions or delays are recorded.
Q4. Can competitors develop similar treatments?
Only if they avoid infringing on claims or obtain licenses; the claims are specific but do not cover all possible formulations.
Q5. What areas are seeing increased patent activity in this therapeutic class?
Combination therapies and delivery innovations such as sustained-release formulations are prominent in recent filings.
References
- European Patent Office. (2023). Patent filing and patent landscape data analysis.
- Serbian Intellectual Property Office. (2023). Patent RS59353 status report.
- World Intellectual Property Organization. (2022). Regional patent reports for the Balkan region.
